RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibitionCarolina Nunes, Frank Speleman, Muhammad Rishfi et al.|Science Advances|2022Cited by 49
Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastomaStéphane Van Haver, Stephen S. Roberts|iScience|2023Cited by 8
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastomaBrian H. Kushner, N K Cheung, Shakeel Modak et al.|Bone Marrow Transplantation|2012Cited by 6